Epithelial to mesenchymal transition tools
Related
Your guide to EMT markers in cancer.
Activation of epithelial to mesenchymal transition (EMT) is a key process in cancer cell metastasis, during which epithelial cells acquire mesenchymal characteristics with an enhancement of cell motility and migration.
EMT is characterised by a loss of epithelial cell markers, such as cytokeratins and E-cadherin, followed by an upregulation in the expression of mesenchymal cell markers, such as N-cadherin, vimentin, and fibronectin.
These epithelial and mesenchymal cell marker expression changes lead to a reduction in adhesion between the transitioning cell and adjacent epithelial cells, and an increase in the secretion of enzymes that degrade the extracellular matrix.1 Collectively, this results in epithelial cells losing apical-basal cell polarity, reorganizing their cytoskeleton, and reprogramming gene expression; enabling the development of an invasive phenotype in cancer metastasis.2
Contents:
E-Cadherin
Decreased E-cadherin expression is a fundamental event in EMT and cancer metastasis and has emerged as a molecular hallmark of the carcinoma EMT.3
We recommend Recombinant Anti-E Cadherin antibody [EP700Y] (ab40772)
Image (above): Immunohistochemistry (formalin/PFA-fixed paraffin-embedded sections) of human breast carcinoma tissue stained using Recombinant Anti-E cadherin antibody [EP700Y] (ab40772) (green).
Browse all E-cadherin antibodies
N-cadherin
The loss of E-cadherin is typically associated with a gain of expression of the mesenchymal marker, N-cadherin, in many cancer types and is thought to be necessary for tumor cells to gain invasive properties.4
We recommend Anti-N Cadherin antibody (ab18203)
Image (above): Immunohistochemistry (formalin/PFA-fixed paraffin-embedded sections) of human liver cancer tissue stained with Anti-N Cadherin antibody (ab18203).
Browse all N-cadherin antibodies
Vimentin
Overexpression of vimentin is correlated with increased invasiveness and metastasis of several cancers.5
We recommend Recombinant Anti-Vimentin antibody [EPR3776] (ab92547).
Image (above): Immunohistochemistry (formalin/PFA-fixed paraffin-embedded sections) of human breast adenocarcinoma tissue stained using Recombinant Anti-Vimentin antibody [EPR3776] (ab92547).
Browse all vimentin antibodies.
SNAIL
The change in the epithelial and mesenchymal gene expression that occurs during EMT is regulated by multiple transcription factor families that include SNAI1/Snail, ZEB1/ZEB2, and basic helix-loop-helix transcription factors (bHLH).2
We recommend Anti-SNAIL + SLUG antibody (ab180714).
Image (above): Immunohistochemistry (formalin/PFA-fixed paraffin-embedded sections) of human cervical carcinoma tissue stained with Recombinant Anti-ZEB1(AREB6) antibody (ab203829).
Browse all SNAIL and SLUG antibodies
Browse all ZEB1/AREB6 antibodies
Browse all ZEB2/SIP1 antibodies
Couldn't find what you were looking for?
View all our relevant EMT products or find out more about how we can support your project with customized proteomic reagents and assays.
References
- Banyard, J. and Bielenberg, D. R. Connect Tissue Res. 2015; 56(5):403–413.
- Lamouille, S., Xu, J., & Derynck, R. Nature Rev: Mol Cell Biol. 2014; 15(3), 178–196.
- Wells, A. et al. Clin & Exper Metastasis. 2008; 25(6), 621–628.
- Jia, W. et al. Anticancer Res. 2015; 35 (5), 2635-2643.
- Vergara, D. et al. EuPA Open Proteomics. 2016; 10, 31-41.